Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031

Table of Contents

About GlobalData

List of Contents

List of Tables

List of Figures

1 Obesity: Executive Summary

1.1 The obesity market will grow significantly during the forecast period, reaching sales of $37.1 billion in 2031

1.2 Key players will maintain their competitive position

1.3 While the outlook in obesity improves, opportunities remain to improve patient outcomes

1.4 Late-stage pipeline therapies are anticipated to drive growth in the obesity market

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Overview

3.1.2 Etiology

3.1.3 Pathophysiology

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.3.1 Total prevalence of overweight

4.3.2 Total prevalence of obesity

4.3.3 Diagnosed prevalence of overweight

4.3.4 Diagnosed prevalence of obesity

4.4 7MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Total prevalent cases of overweight

4.4.4 Total prevalent cases of obesity

4.4.5 Total prevalent cases by BMI class

4.4.6 Diagnosed prevalent cases of overweight, obesity, and obesity by BMI class

4.4.7 Diagnosed incident cases of bariatric surgery

4.5 Epidemiological forecast for overweight and obesity (2021–31)

4.5.1 Total prevalent cases of overweight

4.5.2 Total prevalent cases of obesity

4.5.3 Diagnosed prevalent cases of overweight

4.5.4 Age-specific diagnosed prevalent cases of overweight

4.5.5 Sex-specific diagnosed prevalent cases of overweight

4.5.6 Diagnosed prevalent cases of obesity

4.5.7 Age-specific diagnosed prevalent cases of obesity

4.5.8 Sex-specific diagnosed prevalent cases of obesity

4.5.9 Diagnosed prevalent cases of obesity by BMI class

4.5.10 Diagnosed incident cases of bariatric surgery

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.1.1 Diagnosis overview

5.1.2 Treatment overview

5.2 KOL Insights on Disease Management

5.2.1 Guidelines on diagnosis and treatment

5.2.2 Treatment approach

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Increased efficacy and weight loss maintenance

7.3 Longer-acting therapy

7.4 Cost of therapy

7.5 Increased public awareness

7.6 Availability/accessibility of specialists

8 R&D Strategies

8.1 Overview

8.1.1 Development of novel targets

8.1.2 Development of oral agents

8.2 Clinical Trials Design

8.2.1 Clinical endpoints for obesity

8.2.2 Inclusion and exclusion criteria for obesity

8.2.3 Trial duration

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – key opinion leaders interviewed for this report

13.4.1 Key opinion leaders

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Reviewers

13.6.5 Vice President of Disease Analysis and Intelligence

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

Contact Us

List of Tables

Table 1: Obesity: key metrics in the 7MM

Table 2: Classifications of obesity as outlined by the WHO

Table 3: Classification systems for obesity based on BMI cut-off points

Table 4: Risk factors and comorbidities for obesity

Table 5: Treatment guidelines for obesity

Table 6: Top 10 deals by value, 2017–22

Table 7: Obesity market – global drivers and barriers, 2021–31

Table 8: Key events impacting sales for obesity in the US, 2021–31

Table 9: Obesity market – drivers and barriers in the US, 2021–31

Table 10: Key events impacting sales for obesity in the 5EU, 2021–2031

Table 11: Obesity market – drivers and barriers in the 5EU, 2021–31

Table 12: Key events impacting sales for Obesity in Japan, 2021–31

Table 13: Obesity market – drivers and barriers in Japan, 2021–2031

Table 14: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

Figure 1: Global sales forecast by country for obesity in 2021 and 2031

Figure 2: Analysis of the company portfolio gap in obesity during the forecast period

Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of obesity during the forecast period

Figure 4: Factors involved in the etiology of obesity

Figure 5: Pathophysiological manifestation of obesity

Figure 6: 7MM, total prevalence of overweight, men and women, ages ≥5 years, 2011–31 (%)

Figure 7: 7MM, total prevalence of obesity, men and women, ages ≥5 years, 2011–31 (%)

Figure 8: 7MM, diagnosed prevalence of overweight, men and women, ages ≥5 years, 2011–31 (%)

Figure 9: 7MM, diagnosed prevalence of obesity, men and women, ages ≥5 years, 2011–31 (%)

Figure 10: 7MM, sources used to forecast the total and diagnosed prevalent cases of overweight and obesity

Figure 11: 7MM, sources used and not used to forecast the total and diagnosed prevalent cases of Class I, Class II, and Class III obesity

Figure 12: 7MM, sources used and not used to forecast diagnosed incidence of bariatric surgery

Figure 13: 7MM, total prevalent cases of overweight, men and women, ages ≥5 years, 2021 (N)

Figure 14: 7MM, total prevalent cases of obesity, men and women, ages ≥5 years, 2021 (N)

Figure 15: 7MM, diagnosed prevalent cases of overweight, men and women, ages ≥5 years, 2021 (N)

Figure 16: 7MM, diagnosed prevalent cases of overweight by age, men and women, 2021 (N)

Figure 17: 7MM, diagnosed prevalent cases of overweight by sex, ages ≥5 years, 2021 (N)

Figure 18: 7MM, diagnosed prevalent cases of obesity, men and women, ages ≥5 years, 2021 (N)

Figure 19: 7MM, diagnosed prevalent cases of obesity by age, men and women, 2021 (N)

Figure 20: 7MM, diagnosed prevalent cases of obesity by sex, ages ≥5 years, 2021 (N)

Figure 21: 7MM, diagnosed prevalent cases of obesity by BMI class, men and women, ages ≥5 years, 2021 (N)

Figure 22: 7MM, diagnosed incident cases of bariatric surgery, men and women, all ages, 2021 (N)

Figure 23: BMI chart as a diagnostic technique for obesity

Figure 24: Treatment algorithm for obesity

Figure 25: Unmet needs and opportunities in obesity

Figure 26: Overview of the development pipeline in obesity

Figure 27: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for obesity in the 7MM during the forecast period

Figure 28: Competitive assessment of the recently approved agents and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of obesity during the forecast period

Figure 29: Competitive assessment of the marketed and pipeline drugs benchmarked against the standard of care, Wegovy

Figure 30: Analysis of the company portfolio gap in obesity during the forecast period

Figure 31: Global (7MM) sales forecast by country for obesity in 2021 and 2031

Figure 32: Global (7MM) sales forecast by drug for obesity in 2021 and 2031

Figure 33: Sales forecast by drug for obesity in the US in 2021 and 2031

Figure 34: Sales forecast by drug for obesity in the 5EU in 2021 and 2031

Figure 35: Sales forecast by drug for obesity in Japan in 2021 and 2031